The test is called OVA1 and will be sold by Quest Diagnostics. It allows physicians to assess, before surgery, the likelihood that a woman's mass is malignant. The company says that knowledge could help doctors direct a women to a specialist more quickly.
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States.
It is estimated more than 1 million women will be diagnosed with an ovarian mass this year.
